Comparison of Whole Blood RNA Preservation Tubes and Novel Generation RNA Extraction Kits for Analysis of mRNA and MiRNA Profiles

Background Whole blood expression profiling is frequently performed using PAXgene (Qiagen) or Tempus (Life Technologies) tubes. Here, we compare 6 novel generation RNA isolation protocols with respect to RNA quantity, quality and recovery of mRNA and miRNA. Methods 3 PAXgene and 3 Tempus Tubes were collected from participants of the LIFE study with (n = 12) and without (n = 35) acute myocardial infarction (AMI). RNA was extracted with 4 manual protocols from Qiagen (PAXgene Blood miRNA Kit), Life Technologies (MagMAX for Stabilized Blood Tubes RNA Isolation Kit), and Norgen Biotek (Norgen Preserved Blood RNA Purification Kit I and Kit II), and 2 (semi-)automated protocols on the QIAsymphony (Qiagen) and MagMAX Express-96 Magnetic Particle Processor (Life Technologies). RNA quantity and quality was determined. For biological validation, RNA from 12 representative probands, extracted with all 6 kits (n = 72), was reverse transcribed and mRNAs (matrix metalloproteinase 9, arginase 1) and miRNAs (miR133a, miR1), shown to be altered by AMI, were analyzed. Results RNA yields were highest using the Norgen Kit I with Tempus Tubes and lowest using the Norgen Kit II with PAXgene. The disease status was the second major determinant of RNA yields (LIFE-AMI 11.2 vs. LIFE 6.7 µg, p<0.001) followed by the choice of blood collection tube. (Semi-)automation reduced overall RNA extraction time but did not generally reduce hands-on-time. RNA yields and quality were comparable between manual and automated extraction protocols. mRNA expression was not affected by collection tubes and RNA extraction kits but by RT/qPCR reagents with exception of the Norgen Kit II, which led to mRNA depletion. For miRNAs, expression differences related to collection tubes (miR30b), RNA isolation (Norgen Kit II), and RT/qRT reagents (miR133a) were observed. Conclusion We demonstrate that novel generation RNA isolation kits significantly differed with respect to RNA recovery and affected miRNA but not mRNA expression profiles.

[1]  J. Carstensen,et al.  Circulating Matrix Metalloproteinase-9 Is Associated with Cardiovascular Risk Factors in a Middle-Aged Normal Population , 2008, PloS one.

[2]  F. Sharp,et al.  Blood Biomarkers of Ischemic Stroke , 2011, Neurotherapeutics.

[3]  M. Gerstein,et al.  RNA-Seq: a revolutionary tool for transcriptomics , 2009, Nature Reviews Genetics.

[4]  Peter F. Stadler,et al.  Alu Elements in ANRIL Non-Coding RNA at Chromosome 9p21 Modulate Atherogenic Cell Functions through Trans-Regulation of Gene Networks , 2013, PLoS genetics.

[5]  Y. Devaux,et al.  A Panel of 4 microRNAs Facilitates the Prediction of Left Ventricular Contractility after Acute Myocardial Infarction , 2013, PloS one.

[6]  Justine R. Smith,et al.  Gene expression profiling of whole blood: Comparison of target preparation methods for accurate and reproducible microarray analysis , 2009, BMC Genomics.

[7]  K. Raddassi,et al.  Differential gene expression profiles are dependent upon method of peripheral blood collection and RNA isolation , 2008, BMC Genomics.

[8]  Sandip Chaugai,et al.  Plasma microRNA-133a is a new marker for both acute myocardial infarction and underlying coronary artery stenosis , 2013, Journal of Translational Medicine.

[9]  Xiuhua Liu,et al.  MicroRNA-15a/b are up-regulated in response to myocardial ischemia/reperfusion injury , 2012, Journal of geriatric cardiology : JGC.

[10]  G. Güvenen,et al.  Interleukin-33, matrix metalloproteinase-9, and tissue ınhibitor of matrix metalloproteinase-1 in myocardial infarction , 2013, The Korean journal of internal medicine.

[11]  D. Mehta,et al.  Peripheral blood gene expression: it all boils down to the RNA collection tubes , 2012, BMC Research Notes.

[12]  Hugo A. Katus,et al.  A signature of circulating microRNAs differentiates takotsubo cardiomyopathy from acute myocardial infarction , 2013, European heart journal.

[13]  M. Stayton,et al.  Earliest changes in the left ventricular transcriptome post-myocardial infarction , 2006, Mammalian Genome.

[14]  R. Yeung,et al.  Assessment of sample collection and storage methods for multicenter immunologic research in children. , 2008, Journal of immunological methods.

[15]  M. Gerstein,et al.  The Transcriptional Landscape of the Yeast Genome Defined by RNA Sequencing , 2008, Science.

[16]  Uwe Oelmueller,et al.  Stabilization of mRNA expression in whole blood samples. , 2002, Clinical chemistry.

[17]  Jonathan D. Smith,et al.  Genome-wide studies of gene expression relevant to coronary artery disease , 2012, Current opinion in cardiology.

[18]  Qiang Wang,et al.  MiRNAs as Biomarkers of Myocardial Infarction: A Meta-Analysis , 2014, PloS one.

[19]  Markus Scholz,et al.  Rationale and Design of the Leipzig (LIFE) Heart Study: Phenotyping and Cardiovascular Characteristics of Patients with Coronary Artery Disease , 2011, PloS one.

[20]  B. Williams,et al.  Mapping and quantifying mammalian transcriptomes by RNA-Seq , 2008, Nature Methods.

[21]  M. Mallmann,et al.  High-Resolution Transcriptome of Human Macrophages , 2012, PloS one.

[22]  G. Karypis,et al.  Expression levels for many genes in human peripheral blood cells are highly sensitive to ex vivo incubation , 2004, Genes and Immunity.

[23]  K. Xia,et al.  Circulating microRNAs: A Potential Role in Diagnosis and Prognosis of Acute Myocardial Infarction , 2013, Disease markers.

[24]  D. Fliser,et al.  Circulating miR-210 predicts survival in critically ill patients with acute kidney injury. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[25]  H. Khan,et al.  Blood cell counts and their correlation with creatine kinase and C-reactive protein in patients with acute myocardial infarction. , 2012, International journal of clinical and experimental medicine.

[26]  S. Tan,et al.  DNA, RNA, and Protein Extraction: The Past and The Present , 2009, Journal of biomedicine & biotechnology.

[27]  B. Oliver,et al.  Microarrays, deep sequencing and the true measure of the transcriptome , 2011, BMC Biology.

[28]  Jun Li,et al.  Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multi-ethnic ADVANCE study. , 2008, Human molecular genetics.

[29]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[30]  P. Libby,et al.  Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. , 2000, The Journal of clinical investigation.

[31]  E. Susser,et al.  Human blood RNA stabilization in samples collected and transported for a large biobank , 2012, BMC Research Notes.

[32]  R. Lahesmaa,et al.  Genome-wide comparison of two RNA-stabilizing reagents for transcriptional profiling of peripheral blood. , 2013, Translational research : the journal of laboratory and clinical medicine.